Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For the acute coronary syndrome (ACS) group — there are three types:
- STEMI (a type of heart attack): People who have elevated heart enzyme levels in their blood (indicating heart muscle damage), a specific abnormal pattern on their heart tracing (ECG), AND at least one of: ongoing chest pain from reduced blood flow; an ultrasound showing abnormal heart wall movement; or abnormal findings on a heart artery scan.
- NSTEMI (another type of heart attack): People who have elevated heart enzyme levels in their blood, AND at least one of: ongoing chest pain from reduced blood flow; specific changes on their heart tracing; an ultrasound showing abnormal heart wall movement; or abnormal findings on a heart artery scan.
- Unstable Angina (UA): People with normal heart enzyme levels, chest pain with specific changes on their heart tracing, AND evidence of a blockage of 50% or more in a heart artery (confirmed by imaging).
For the chronic coronary syndrome (CCS) group — people living with long-term heart artery disease:
- People with a doctor's diagnosis fitting one of these categories: stable chest pain, heart muscle weakening due to reduced blood flow, a stable phase after a previous heart attack, long-term management of heart artery disease, artery spasm or small vessel disease, or heart artery disease with no symptoms.
- People whose heart tracing shows no signs of an active heart attack, whose heart enzyme levels are normal or stable, AND who have at least one heart artery with a 50% or greater blockage confirmed by imaging.
For the control group:
- People who do not have any blockages in their heart arteries, heart valve problems, structural heart problems, or any form of heart muscle disease.
Who may not be able to join:
- Women who are currently pregnant or breastfeeding
- People who have been diagnosed with a malignant cancer (confirm with trial site)
- People with severely reduced liver or kidney function
- People with severe disorders affecting the blood or blood cells
- People with autoimmune diseases (conditions where the immune system attacks the body)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86+18267806867
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
circulating fibroblast growth factors (FGFs) levels; circulating inflammatory cytokines levels; circulating chemokines levels; circulating Cytochrome C level; circulating mitochondrial DNA levels; circulating malondialdehyde levels
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.